The US FTC challenges a merger using a monopolization theory to allege that the merger would eliminate nascent competition in the therapeutic adrenocorticotropic hormones (Questcor Pharmaceuticals / Mallinckrodt)

Heltzer, Gregory E.

Previous article The EU Commission clears a merger subject to remedies in the pharmaceutical sector (Abbott / Alere) Next article The Indian Competition Authority fines merging parties for failure to disclose the global acquisition of a healthcare antisepsis business (Schulke / ASP Division of Ethicon)

18 Jan 2017

The US FTC challenges a merger using a monopolization theory to allege that the merger would eliminate nascent competition in the therapeutic adrenocorticotropic hormones (Questcor Pharmaceuticals / Mallinckrodt)

KEYWORDS

Reference

US FTC, Questcor Pharmaceuticals / Mallinckrodt, Press Release, 18 January 2017

The Federal Trade Commission (FTC) challenged a consummated transaction using a monopolization theory to allege that the acquisition would eliminate “nascent” competition for therapeutic adrenocorticotropic hormones (ACTH) in the United States. WHAT HAPPENED: Questcor Pharmaceuticals, Inc.’s (Questcor) H.P. Acthar Gel (Acthar) is the only ACTH product sold in the US, is the standard of care for

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Gregory E. Heltzer
McDermott Will & Emery (Washington)

United States 35 contributions 5703 visits

Quotation

Gregory E. Heltzer, The US FTC challenges a merger using a monopolization theory to allege that the merger would eliminate nascent competition in the therapeutic adrenocorticotropic hormones (Questcor Pharmaceuticals / Mallinckrodt), 18 January 2017, e-Competitions Pharma & Mergers, Art. N° 93369

Visites 119